Rationalizing responses to Aurora B inhibitors in leukaemia

合理化 Aurora B 抑制剂治疗白血病的反应

• 批准号: 2111659
• 金额: --
• 依托单位: Queen Mary University of London
• 依托单位国家: 英国
• 项目类别: Studentship
• 财政年份: 2018
• 资助国家: 英国
• 起止时间: 2018 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=studentship-2111659
• 关键词: Rationalizing; responses; Aurora; inhibitors; leukaemia

Acute myeloid leukaemia (AML), the most common form of acute leukaemia, remains incurable for most patients. New targeted therapies based on kinase inhibitors are being tested in AML, but not all patients benefit to the same extent, highlighting the need for personalized treatments. Previous work has shown promise for Aurora B inhibitors in AML. Here, the student will take proteomic and system biology approaches to investigate the mechanisms that sensitize AML cells to Aurora B targeted therapy. In addition to advancing our understanding of Aurora B role in cancer biology, this work has the potential to impact AML personalized therapy.Aurora kinases play prominent roles in cancer biology (Ref 1) and clinical trials evaluating Aurora B inhibitors in acute myeloid leukaemia (AML) are showing promise. However, not all patients respond to these therapies to the same extent and the mechanisms that allow cancer cells to evade treatment are not fully understood. The aim of this project is to investigate the mode of action of Aurora B inhibitors in AML cells and the biochemical mechanisms that make cancer cells sensitive or resistant to these compounds. To this end, the student will compare the wiring of biochemical networks in cell lines of different sensitivity profile to Aurora B inhibitors and will investigate how such biochemical wiring changes upon therapy. This will be achieved by using state-of-the-art proteomic and phosphoproteomic methods in combination with computational approaches to derive biochemical network topology from such datasets. These methodologies are well developed in the host laboratory and their application in different cancer models has shown that responses to kinase inhibitors are determined by the combination of the activity of both the target and parallel pathways (Refs 2-5). The hypotheses generated with the initial cell-based work will be tested in additional AML cell lines, primary AML samples obtained from the BCI tissue biobank and in those derived from current and planned Aurora B inhibitors clinical trials in AML. In addition to advancing our understanding of how Aurora Bcontrols cancer biology, signatures associated with patient responses may represent biomarkers for patient stratification and personalized medicine.The project will train the student in mass spectrometry-based proteomics and computational biology applied to the investigation of intracellular cell signaling and cancer research. These unique combination of skills are in short supply in the UK and are highly valued by industry and academia.

急性髓性白血病（AML）是急性白血病的最常见形式，对大多数患者来说仍然无法治愈。基于激酶抑制剂的新靶向疗法正在AML中进行测试，但并非所有患者都能在相同程度上受益，这凸显了个性化治疗的必要性。以前的工作已经显示出Aurora B抑制剂在AML中的前景。在这里，学生将采取蛋白质组学和系统生物学的方法来调查的机制，敏感的AML细胞极光B靶向治疗。除了推进我们对Aurora B在癌症生物学中作用的理解，这项工作有可能影响AML个性化治疗。Aurora激酶在癌症生物学中发挥重要作用（参考文献1），评估Aurora B抑制剂在急性髓性白血病（AML）中的临床试验显示出希望。然而，并非所有患者对这些疗法的反应程度相同，并且允许癌细胞逃避治疗的机制尚未完全了解。该项目的目的是研究Aurora B抑制剂在AML细胞中的作用模式以及使癌细胞对这些化合物敏感或耐药的生化机制。为此，学生将比较不同敏感性细胞系中的生化网络对Aurora B抑制剂的连接，并研究治疗后这种生化连接的变化。这将通过使用最先进的蛋白质组学和磷酸化蛋白质组学方法结合计算方法从这些数据集获得生化网络拓扑来实现。这些方法在宿主实验室中得到了很好的开发，它们在不同癌症模型中的应用表明，对激酶抑制剂的反应是由靶途径和平行途径的活性组合决定的（参考文献2-5）。将在额外的AML细胞系、从BCI组织生物库获得的原代AML样本以及来自当前和计划的Aurora B抑制剂AML临床试验的样本中检验初始基于细胞的工作产生的假设。除了推进我们对Aurora Bcontrols癌症生物学的理解，与患者反应相关的特征可能代表患者分层和个性化医疗的生物标志物。该项目将培养学生基于质谱的蛋白质组学和计算生物学，应用于细胞内信号传导和癌症研究的调查。这些独特的技能组合在英国供不应求，受到工业界和学术界的高度重视。